Chanakyaram A Reddy1, Anna Tavakkoli2, Vincent L Chen3, Sheryl Korsnes3, Aarti Oza Bedi3, Philip W Carrott4, Andrew C Chang5, Kiran H Lagisetty5, Richard S Kwon3, B Joseph Elmunzer6, Mark B Orringer5, Cyrus Piraka7, Anoop Prabhu3, Rishindra M Reddy5, Erik Wamsteker3, Joel H Rubenstein3. 1. Barrett's Esophagus Program, Division of Gastroenterology, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI, 48109, USA. shanreddy13@gmail.com. 2. Division of Gastroenterology, UT Southwestern, Dallas, TX, USA. 3. Barrett's Esophagus Program, Division of Gastroenterology, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI, 48109, USA. 4. Division of Thoracic Surgery, Baylor College of Medicine, Houston, TX, USA. 5. Section of Thoracic Surgery, University of Michigan, Ann Arbor, MI, USA. 6. Division of Gastroenterology, Medical University of South Carolina, Charleston, SC, USA. 7. Division of Gastroenterology, Henry Ford Health System, Detroit, MI, USA.
Abstract
INTRODUCTION: Endoscopic therapy (ET) and esophagectomy result in similar survival for Barrett's esophagus (BE) with high-grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC), but the long-term quality of life (QOL) has not been compared. AIMS: We aimed to compare long-term QOL between patients who had undergone ET versus esophagectomy. METHODS: Patients were included if they underwent ET or esophagectomy at the University of Michigan since 2000 for the treatment of HGD or T1a EAC. Two validated survey QOL questionnaires were mailed to the patients. We compared QOL between and within groups (ET = 91, esophagectomy = 62), adjusting for covariates. RESULTS: The median time since initial intervention was 6.8 years. Compared to esophagectomy, ET patients tended to be older, had a lower prevalence of EAC, and had a shorter duration since therapy. ET patients had worse adjusted physical and role functioning than esophagectomy patients. However, the adjusted odds ratio (OR) of having symptoms was significantly less with ET for diarrhea (0.287; 95% confidence interval [CI] = 0.114, 0.724), trouble eating (0.207; 0.0766, 0.562), choking (0.325; 0.119, 0.888), coughing (0.291; 0.114, 0.746), and speech difficulty (0.306; 0.0959, 0.978). Amongst the ET patients, we found that the number of therapy sessions and need for dilation were associated with worse outcomes. DISCUSSION: Multiple measures of symptom status were better with ET compared to esophagectomy following treatment of BE with HGD or T1a EAC. We observed worse long-term physical and role functioning in ET patients which could reflect unmeasured baseline functional status rather than a causal effect of ET.
INTRODUCTION: Endoscopic therapy (ET) and esophagectomy result in similar survival for Barrett's esophagus (BE) with high-grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC), but the long-term quality of life (QOL) has not been compared. AIMS: We aimed to compare long-term QOL between patients who had undergone ET versus esophagectomy. METHODS: Patients were included if they underwent ET or esophagectomy at the University of Michigan since 2000 for the treatment of HGD or T1a EAC. Two validated survey QOL questionnaires were mailed to the patients. We compared QOL between and within groups (ET = 91, esophagectomy = 62), adjusting for covariates. RESULTS: The median time since initial intervention was 6.8 years. Compared to esophagectomy, ET patients tended to be older, had a lower prevalence of EAC, and had a shorter duration since therapy. ET patients had worse adjusted physical and role functioning than esophagectomy patients. However, the adjusted odds ratio (OR) of having symptoms was significantly less with ET for diarrhea (0.287; 95% confidence interval [CI] = 0.114, 0.724), trouble eating (0.207; 0.0766, 0.562), choking (0.325; 0.119, 0.888), coughing (0.291; 0.114, 0.746), and speech difficulty (0.306; 0.0959, 0.978). Amongst the ET patients, we found that the number of therapy sessions and need for dilation were associated with worse outcomes. DISCUSSION: Multiple measures of symptom status were better with ET compared to esophagectomy following treatment of BE with HGD or T1a EAC. We observed worse long-term physical and role functioning in ET patients which could reflect unmeasured baseline functional status rather than a causal effect of ET.
Entities:
Keywords:
Endoscopic mucosal resection; Quality of life; Radiofrequency ablation
Authors: N Li; S Pasricha; W J Bulsiewicz; R E Pruitt; S Komanduri; H C Wolfsen; G W Chmielewski; F S Corbett; K J Chang; N J Shaheen Journal: Dis Esophagus Date: 2015-06-30 Impact factor: 3.429
Authors: R Parameswaran; A McNair; K N L Avery; R G Berrisford; S A Wajed; M A G Sprangers; J M Blazeby Journal: Ann Surg Oncol Date: 2008-07-15 Impact factor: 5.344
Authors: J M Blazeby; T Conroy; E Hammerlid; P Fayers; O Sezer; M Koller; J Arraras; A Bottomley; C W Vickery; P L Etienne; D Alderson Journal: Eur J Cancer Date: 2003-07 Impact factor: 9.162
Authors: Cathy Bennett; Paul Moayyedi; Douglas A Corley; John DeCaestecker; Yngve Falck-Ytter; Gary Falk; Nimish Vakil; Scott Sanders; Michael Vieth; John Inadomi; David Aldulaimi; Khek-Yu Ho; Robert Odze; Stephen J Meltzer; Eamonn Quigley; Stuart Gittens; Peter Watson; Giovanni Zaninotto; Prasad G Iyer; Leo Alexandre; Yeng Ang; James Callaghan; Rebecca Harrison; Rajvinder Singh; Pradeep Bhandari; Raf Bisschops; Bita Geramizadeh; Philip Kaye; Sheila Krishnadath; M Brian Fennerty; Hendrik Manner; Katie S Nason; Oliver Pech; Vani Konda; Krish Ragunath; Imdadur Rahman; Yvonne Romero; Richard Sampliner; Peter D Siersema; Jan Tack; Tony C K Tham; Nigel Trudgill; David S Weinberg; Jean Wang; Kenneth Wang; Jennie Y Y Wong; Stephen Attwood; Peter Malfertheiner; David MacDonald; Hugh Barr; Mark K Ferguson; Janusz Jankowski Journal: Am J Gastroenterol Date: 2015-04-14 Impact factor: 10.864
Authors: Mirjam C M van der Ende-van Loon; A Stoker; P T Nieuwkerk; W L Curvers; E J Schoon Journal: Qual Life Res Date: 2021-11-08 Impact factor: 3.440